[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Children's Hospital, Vietnam\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636349","efficacy-and-safety-of-a-combined-dexmedetomidine-ketamine-sedation-regimen-for-pediatric-cardiac-catheterization-100636349",false,"NCT07564531","Efficacy and Safety of a Combined Dexmedetomidine-Ketamine Sedation Regimen for Pediatric Cardiac Catheterization","Evaluation of the Efficacy and Safety of a Combined Dexmedetomidine-Ketamine Sedation Regimen for Pediatric Cardiac Catheterization at Vietnam National Children's Hospital","KETADEX","Inclusion Criteria:\n\n* Patients under 18 years of age.\n* Patients indicated for diagnostic or interventional cardiac catheterization.\n\nExclusion Criteria:\n\n* Patients with acute respiratory infections, chromosomal abnormalities, metabolic disorders, or other co-existing medical conditions.\n* Arrhythmias, second- or third-degree atrioventricular (AV) block; patients on mechanical ventilation or requiring vasopressors prior to the procedure.\n* Known history of allergy or hypersensitivity to dexmedetomidine, ketamine, propofol, midazolam, or sevoflurane.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if the spontaneous sedation regimen of dexmedetomidine-ketamine (KETADEX) has the comparable efficacy and safety in pediatric cardiac catheterization versus the traditional regimen. The main question it aims to answer is:\n\nIs the combined Dexmedetomidine-Ketamine spontaneous sedation regimen (KETADEX) non-inferior to the traditional general anesthesia regimen in terms of efficacy and safety?\n\nParticipants would received either KETADEX regimen or general anesthesia regimen. Research members then observe the catheterization procedure and answer the questionnaire about their efficacy and safety.",[25,26],"Cardiac Catheterization","Pediatric",[28,29,30,31,32],"dexmedetomidine","ketamine","spontaneous sedation","general anesthesia","cardiac catheterization","RECRUITING","2026-04-29",{"date":36,"type":37},"2026-05-04","ACTUAL",{"date":39,"type":37},"2026-02-04",{"date":41,"type":21},"2026-12-30",{"name":43,"class":44},"National Children's Hospital, Vietnam","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100635666","therapeutic-hypothermia-for-neonatal-hypoxic-ischemic-encephalopathy-in-vietnam-100635666","NCT07555652","Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy in Vietnam","Efficacy of Controlled Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy (HIE)","HIE-TH Vietnam","Inclusion Criteria:\n\n* Neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) at the Neonatal Center, National Children's Hospital\n* Gestational age ≥ 36 weeks\n* Assessed using the modified Sarnat staging within the first 0-6 hours after birth\n* Eligible for and\u002For treated with therapeutic hypothermia according to institutional protocol\n* Underwent clinical and paraclinical monitoring during hospitalization\n* Received brain magnetic resonance imaging (MRI) during the neonatal period (from 5 to 17 days of age)\n* Availability of complete medical records for data collection and analysis\n\nExclusion Criteria:\n\n* Presence of major congenital anomalies, particularly involving the central nervous system\n* Absence of brain MRI during the study period\n* Refusal of participation by parent(s) or legal guardian(s)","0 Hours","6 Hours",{"count":57,"type":21},120,"INTERVENTIONAL",[60],"NA","This study aims to evaluate the effectiveness of therapeutic hypothermia in neonates diagnosed with hypoxic-ischemic encephalopathy (HIE). The study focuses on assessing both short-term outcomes after treatment and long-term neurological outcomes following therapeutic hypothermia.",[63],"Hypoxic-ischemic Encephalopathy (HIE)","2026-04-21",{"date":34,"type":37},{"date":67,"type":37},"2025-06-10",{"date":69,"type":21},"2028-02-01",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":58,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100633470","autologous-bone-marrow-mononuclear-cell-transplantation-combined-with-rehabilitation-in-children-with-sequelae-of-hypoxic-ischemic-encephalopathy-or-intracranial-hemorrhage-100633470","NCT07527104","Autologous Bone Marrow Mononuclear Cell Transplantation Combined With Rehabilitation in Children With Sequelae of Hypoxic-Ischemic Encephalopathy or Intracranial Hemorrhage","A Randomized Controlled Trial Evaluating the Efficacy and Safety of Autologous Bone Marrow-Derived Mononuclear Cell Transplantation Combined With Rehabilitation in Children With Sequelae of Hypoxic-Ischemic Encephalopathy or Intracranial Hemorrhage","BMMCT-CP","Inclusion Criteria:\n\n* Children diagnosed with cerebral palsy\n* Age from 12 months to 72 months\n* Cerebral palsy caused by hypoxic-ischemic brain injury or intracranial hemorrhage\n* Gross Motor Function Classification System (GMFCS) level III to V\n* Completed required laboratory tests according to the study protocol\n* Written informed consent obtained from the child's parent or legal guardian\n\nExclusion Criteria:\n\n* Children with acute infection at the time of screening or enrollment\n* Children with severe coagulopathy or contraindications to bone marrow aspiration\n* Children with severe systemic diseases (e.g., severe cardiac, hepatic, or renal failure)\n* Children with contraindications to anesthesia or intrathecal transplantation procedures\n* Children with a history of malignancy\n* Children who are unable to participate in or complete the rehabilitation program\n* Parents or legal guardians who do not provide informed consent","6 Months",{"count":81,"type":21},60,[60],"This study evaluates the safety and preliminary efficacy of autologous bone marrow mononuclear cell transplantation combined with rehabilitation in children with neurological sequelae caused by hypoxic-ischemic brain injury or intracranial hemorrhage. Participants in the intervention group will receive autologous bone marrow aspiration, mononuclear cell transplantation via intrathecal route, and rehabilitation, while the control group will receive rehabilitation alone. Outcomes will be compared between groups over follow-up time points.",[85],"Cerebral Palsy Hypoxic-Ischemic Encephalopathy Intracranial Hemorrhage",[87],"Bone Marrow Mononuclear Cells Autologous Transplantation Intrathecal Injection Rehabilitation Pediatric Brain Injury","2026-04-08",{"date":90,"type":37},"2026-04-14",{"date":92,"type":37},"2025-12-15",{"date":94,"type":21},"2028-04-01",{"name":43,"class":44},""]